辉瑞(PFE.US)Q4业绩超预期但投资者更关注减肥药能否扛起增长大旗

智通财经02-03

智通财经APP获悉，周二，辉瑞(PFE.US)公布了第四季度财报，尽管新冠相关产品需求持续萎缩，但公司营收与利润仍双双超出市场预期，同时公司重申了2026年的温和指引——该指引在去年12月公布时曾引发投资者担忧。另外，辉瑞还公布了其新型减肥疗法的初步数据，但披露信息有限。财报显示，辉瑞四季度营收175.6亿美元，同比微降约1%，营收下滑主要源于新冠疫苗及新冠口服药Paxlovid的需求走低：新冠...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2608787921?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-03 21:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608787921","market":"fut","top_or_hot":-1,"title":"辉瑞(PFE.US)Q4业绩超预期 但投资者更关注减肥药能否扛起增长大旗","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，周二，辉瑞(PFE.US)公布了第四季度财报，尽管新冠相关产品需求持续萎缩，但公司营收与利润仍双双超出市场预期，同时公司重申了2026年的温和指引——该指引在去年12月公布时曾引发投资者担忧。另外，辉瑞还公布了其新型减肥疗法的初步数据，但披露信息有限。财报显示，辉瑞四季度营收175.6亿美元，同比微降约1%，营收下滑主要源于新冠疫苗及新冠口服药Paxlovid的需求走低：新冠...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1401242.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>辉瑞(PFE.US)Q4业绩超预期 但投资者更关注减肥药能否扛起增长大旗</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n辉瑞(PFE.US)Q4业绩超预期 但投资者更关注减肥药能否扛起增长大旗\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-03 21:06 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1401242.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，周二，辉瑞(PFE.US)公布了第四季度财报，尽管新冠相关产品需求持续萎缩，但公司营收与利润仍双双超出市场预期，同时公司重申了2026年的温和指引——该指引在去年12月公布时曾引发投资者担忧。另外，辉瑞还公布了其新型减肥疗法的初步数据，但披露信息有限。财报显示，辉瑞四季度营收175.6亿美元，同比微降约1%，营收下滑主要源于新冠疫苗及新冠口服药Paxlovid的需求走低：新冠...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1401242.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999002224.SGD","symbol_name":"Allianz Global High Payout SGD","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1401242.html","article_id":"2608787921","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608787921","pubTimestamp":1770123978,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，周二，辉瑞公布了第四季度财报，尽管新冠相关产品需求持续萎缩，但公司营收与利润仍双双超出市场预期，同时公司重申了2026年的温和指引——该指引在去年12月公布时曾引发投资者担忧。另外，辉瑞还公布了其新型减肥疗法的初步数据，但披露信息有限。作为交换，辉瑞将获得为期三年的关税豁免。不过，在财报公布后，辉瑞股价盘前仍跌逾5%。他认为，辉瑞需要凭借在疗效或安全性上显著更优的产品，才能在该领域立足。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"SG9999002224.SGD":"Allianz Global High Payout SGD","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","BK4592":"伊斯兰概念","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","BK4568":"美国抗疫概念","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","BK4588":"碎股","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","BK4550":"红杉资本持仓","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","BK4007":"制药","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0122379950.USD":"贝莱德世界健康科学A2","LU0058720904.USD":"联博国际健康护理基金A","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","LU0234572021.USD":"高盛美国核心股票组合Acc","SG9999001176.USD":"United Global Healthcare Acc USD","BK4581":"高盛持仓","BK4599":"减肥药","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","PFE":"辉瑞","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","SG9999002232.USD":"Allianz Global High Payout USD","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC"},"translate_title":"Pfizer's (PFE.US) Q4 performance exceeded expectations, but investors were more concerned about whether diet pills could carry the banner of growth","themeId":"4466d9e38820302c3ea1a8f2a1598904","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":1.97},"content_text":"智通财经APP获悉，周二，辉瑞(PFE.US)公布了第四季度财报，尽管新冠相关产品需求持续萎缩，但公司营收与利润仍双双超出市场预期，同时公司重申了2026年的温和指引——该指引在去年12月公布时曾引发投资者担忧。另外，辉瑞还公布了其新型减肥疗法的初步数据，但披露信息有限。财报显示，辉瑞四季度营收175.6亿美元，同比微降约1%，营收下滑主要源于新冠疫苗及新冠口服药Paxlovid的需求走低：新冠疫苗销售额为23亿美元，虽高于20亿美元的预期，但同比下降三分之一;Paxlovid销售额仅为2.18亿美元，远低于5.89亿美元的预期，同比暴跌超过三分之二。不过，这一数字高于市场预期的169.5亿美元，原因是辉瑞的多款重磅药物整体表现符合预期：尽管其明星肺炎疫苗Prevnar面临默沙东(MRK.US)新产品的竞争，但仍实现17亿美元销售额，略高于16亿美元的预期;抗凝血药Eliquis销售额达20亿美元，心脏病药物Vyndaqel销售额为17亿美元，均符合市场预测。期内公司录得净亏损16.5亿美元，合每股亏损0.29美元;而上年同期公司实现净利润4.1亿美元，合每股收益0.07美元。若剔除重组费用、无形资产相关成本等非经常性项目，公司四季度调整后每股收益为0.66美元，市场预期为0.57美元。展望未来，辉瑞维持2026年业绩指引不变：调整后每股收益预计在2.80-3.00美元之间，营收预计为595-625亿美元，营收规模与2025年基本持平。公司此前曾表示，2026年营收前景平淡，部分原因是新冠疫苗和Paxlovid的销售持续下滑，预计这两类产品全年营收将同比减少约15亿美元，至50亿美元。除新冠产品外，多款产品失去市场独占权，也将导致辉瑞全年营收同比再减少约15亿美元。包括Prevnar在内的多款药物正面临日益激烈的市场竞争。辉瑞首席财务官Dave Denton去年12月还向投资者表示，2026年业绩指引中已充分考虑价格压缩和利润率收窄的影响。作为与美国总统特朗普达成的标志性药品定价协议的一部分，辉瑞计划在医疗补助计划(Medicaid)业务中提供更大幅度的折扣。根据该协议，辉瑞同意以其他发达国家的最低售价，向医疗补助计划参保患者供应现有药物;同时承诺为联邦医疗保险(Medicare)、医疗补助计划及商业保险机构，提供同等的“最惠国”药品定价。作为交换，辉瑞将获得为期三年的关税豁免。今年1月，辉瑞的类风湿关节炎治疗药物Xeljanz及Xeljanz XR被纳入医疗保险药品价格谈判第三轮名单，谈判后的新价格将于2028年生效。新型减肥药能否填补营收缺口仍存疑为对冲新冠产品销售下滑及老牌药物营收萎缩的影响，这家制药巨头正将目光投向管线产品的长期投资，其中包括以100亿美元收购肥胖症生物科技公司Metsera。辉瑞在本次业绩发布中同步披露了Metsera一款肥胖症注射剂的二期临床数据，该药物可实现每月一次给药，且能为患者带来显著的减重效果，这让市场看到了这笔收购的潜在价值。不过，在财报公布后，辉瑞股价盘前仍跌逾5%。由于此次临床试验披露的细节信息十分有限，投资者也因此心生疑虑：公司高价收购Metsera的交易，能否填补新冠疫苗与口服药业务营收下滑带来的业绩缺口。临床数据显示，用药28周后，受试者体重较安慰剂组最多减轻12.3%。分析师指出，要准确评估该药物在目前由诺和诺德(NVO.US)与礼来(LLY.US)主导的快速演变市场中的定位，仍需更多详细信息。瑞穗医疗行业专家Jared Holz表示：“当前市场由两家根基深厚的公司牢牢掌控。”他认为，辉瑞需要凭借在疗效或安全性上显著更优的产品，才能在该领域立足。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2608787921","isCrawlerRequest":true}

辉瑞(PFE.US)Q4业绩超预期 但投资者更关注减肥药能否扛起增长大旗

精彩评论

辉瑞(PFE.US)Q4业绩超预期但投资者更关注减肥药能否扛起增长大旗